About Drug Development Solutions

We help develop new medicines and products to improve the quality of life

Drug Development Solutions is a contract research organisation (CRO) offering GLP and GCP bioanalysis of small molecules, large proteins for pharmacokinetics, biomarkers and immunogenicity. We also provide cGMP analytical sciences research and testing services, consultancy and quality control solutions to support Chemistry Manufacturing and Control (CMC) requirements at all stages of the drug development pipeline from discovery through preclinical and clinical development to commercial manufacture.

Our Cambridge (Fordham) site is one of the largest bioanalytical centres in the world. The site employs around 380 scientists operating from 8,000m2 purpose-built, state-of-the-art analytical labs.

Drug Development Solutions were recently acquired by Alliance Pharma. 

Our Drug Development Solutions' team provides:

Bioanalytical Solutions include liquid-chromatography mass spectrometry (LC-MS) and immunoassay bioanalysis, to provide data for pharmacokinetics, immunogenicity, pharmacodynamics and cell-based assays supporting all phases of drug development to GCP and GLP standards.

Our Analytical Materials Science Solutions provides specialist testing of raw materials, formulated products, packaging and medical devices for trace impurities, contamination, degradation and quality control to support CMC (Chemistry Control and Manufacture) analytical testing to GMP (Good Manufacturing Practice) standard.

The Alliance Pharma team specialise in Drug Metabolism and Pharmacokinetic (DMPK) and bioanalytical services for both small and large molecules. 

U.S. Alliance Pharma Acquires UK-based LGC’s Drug Development Solutions Business (DDS)
Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry recently  closed on the purchase of Drug Development Solutions Business (DDS) from LGC. Ampersand Capital Partners, a healthcare private equity firm and KKR & Co. Inc. (KKR) (NYSE:KKR) a leading global investment firm, will become equal shareholders in the combined company.

Alliance Pharma acquires LGC’s Drug Development Solutions Business Unit